Leaders of CCPIT attend the working conference of China Federation of industry and Economics

Source: Song Ruilin, executive chairman of China Association for the promotion of drugs on December 1, 2011, was invited to make a special introduction of experience, which was highly praised by the participants On November 30, song Ruilin, executive chairman of CFIUS, attended the "2011 work conference of escrow Association" held by China Federation of industrial economics and made a special introduction of experience The work and achievements of CFIUS over the past year were highly appraised by leaders of CFIUS and all participants In 2011, under the cordial care and correct leadership of vice chairman sang Guowei, with the strong support and joint efforts of all governing units and member units, the China Pharmaceutical Industry Research and Development Promotion Association (hereinafter referred to as the Association) focused on the purpose of "innovation, industrialization and internationalization", in promoting the innovation of the pharmaceutical industry, strengthening policy research, carrying out international exchange and medical information work A lot of work has been done to improve the internal management system, and the results are obvious to all 1、 Promoting the innovation and development of the pharmaceutical industry and promoting the innovation and development of the pharmaceutical industry in China has become the focus of the work of the pharmaceutical Council In 2011, the CCPIT mainly did the following six work in this regard: 1 On March 1, it hosted the Beijing report meeting of the 12th Five Year Plan, a major science and technology special project of "major new drug creation" The conference was jointly sponsored by Beijing Municipal Health Bureau, Beijing Municipal Science and Technology Commission, Beijing Municipal Drug Administration, Beijing Municipal Administration of traditional Chinese medicine, and "major new drug creation" science and technology major special implementation management office Vice chairman sang Guowei attended the conference and made a thematic report on the development strategy and current situation of innovative drugs More than 500 representatives from some "two sessions", major scientific and technological special units, medical research institutions, hospital experts, pharmaceutical enterprises and relevant associations attended the report meeting 2 On June 25, the second "Summit Forum of cerebrovascular disease innovative drug industry alliance" was held The theme of this year's forum is "International Forum on comparative effectiveness of Cerebrovascular Research" The forum officially launched the ceremony of "12th Five Year Plan IV clinical trials - enbip injection project", and invited domestic and foreign experts to make a series of special reports on comparative effectiveness of Cerebrovascular Research (CER) 3 Hold academic reports At the second session of the ninth session of the General Assembly on July 5, CFDA invited academician sang Guowei, vice chairman of the Standing Committee of the National People's Congress, and relevant persons from the safety supervision department of the State Food and drug administration to make a report 4 From August 5 to 6, the second China Hospital Pharmacy Forum was held The forum has set up a communication platform for clinicians and clinical pharmacists for the first time, creating a precedent for communication and cooperation between doctors and pharmacists on rational drug use 5 On August 12, we jointly held the achievement conference and national listing meeting of exetinib hydrochloride (trade name: Kemena) with member enterprise Zhejiang Beida Pharmaceutical Co., Ltd in the Great Hall of the people The successful listing of exetinib hydrochloride marks China's zero breakthrough in the field of small molecule targeted anti-tumor drugs, providing more Chinese patients with advanced non-small cell lung cancer with cheap and high-quality domestic targeted anti-tumor drugs, breaking the monopoly position of imported tumor drugs in the Chinese market 6 On November 16, a joint meeting was held with Zhejiang Beida Pharmaceutical Co., Ltd., a member enterprise, to collect and monitor safety information after the launch of "Kemena" and follow-up research on free drug use At the kick-off meeting, the drug promotion association and Beida pharmaceutical signed a cooperation agreement on collection and monitoring of safety information and continuous free drug use after Kemena's listing As an industry organization promoting innovation in the pharmaceutical industry, the drug promotion association will provide services for Kemena's phase IV clinical research and follow-up free drug use 2、 Different from most industry associations, the pharmaceutical promotion association has a special research institution - "Research Center for the development of pharmaceutical industry" With the support of the Ministry of health and other relevant departments and pharmaceutical enterprises, the research center has more than ten full-time researchers, who are responsible for the research of major policy and legal issues related to the pharmaceutical industry, providing reference and suggestions for the government to formulate relevant policies for the development of the pharmaceutical industry and health care, and providing advisory services for the member units in terms of industrial development policies and strategies At present, the research center is engaged in a total of 13 research projects, involving the basic drug system, pharmaceutical intellectual property rights, national drug policy, drug pricing, public hospital reform, pharmaceutical innovation policy, etc 3、 To carry out international exchange and cooperation extensively has become an important part of the work of CFDA Through contact and cooperation with foreign pharmaceutical industry associations and international organizations, CFDA hopes to build a platform for member units to explore the international market, learn foreign advanced technology and management experience In 2011, CICAD mainly carried out the following three international exchange activities: 1 Jointly held the third China US pharmaceutical industry summit with the American pharmaceutical research and Manufacturers Association (PhRMA) to further deepen the strategic partnership On October 18-19, 2011, with the strong support of China International Chamber of Commerce and American Chamber of Commerce, China Council for the promotion of drugs and pharma co hosted the third China US pharmaceutical industry summit in Beijing, which was the first summit since the two associations signed a long-term cooperation framework agreement The theme of the summit is "intellectual property protection and innovation and development of the pharmaceutical industry" At the summit, experts from China and the United States made a number of keynote reports on "legal system of pharmaceutical intellectual property", "protection of pharmaceutical intellectual property and innovation and development of medicine", "protection of pharmaceutical intellectual property and public health rights", "development and protection strategy of pharmaceutical intellectual property", and conducted in-depth exchanges and discussions in the form of interactive questions and round tables After the summit, the two associations jointly signed the Joint Declaration on strengthening the protection of intellectual property rights, promoting the innovation and development of the pharmaceutical industry and improving the level of public health on the basis of consensus, marking a new level of exchanges and cooperation between the pharmaceutical industry of China and the United States 2 Exchange with bio and establish strategic partnership At the end of March, the drug promotion association organized the Chinese pharmaceutical enterprises to exchange with the visiting us Biopharmaceutical Enterprises delegation organized by the US global biotechnology industry organization (bio) Subsequently, the Council signed a strategic cooperation agreement with the US bio According to the agreement, the drug promotion association and bio will work closely together to encourage pharmaceutical innovation as a common goal, establish bilateral mutually beneficial relations for members of both sides, and carry out various forms of exchanges and cooperation Through this event, the biomedical industry of China and the United States has deepened their understanding and friendship 3 He joined China International Chamber of Commerce and initiated the establishment of "biomedical committee" China Council for the promotion of drugs joined the International Chamber of Commerce of China in January this year and became the executive director unit At the beginning of May, China Council for the promotion of drugs, entrusted by China International Chamber of Commerce, jointly initiated the establishment of "China International Chamber of Commerce biomedical committee" with a number of domestic biomedical enterprises The establishment of the professional committee will further promote China's Biopharmaceutical Enterprises to fully participate in international competition and seize the commanding height of the biopharmaceutical industry 4 Exchange and cooperation with the International Federation of Pharmaceutical Manufacturers Associations At this year's China US pharmaceutical industry summit, CFDA specially invited officials from the International Federation of Pharmaceutical Manufacturers Associations to attend the meeting and make a special report On November 30, the association held a conference call with the association to discuss specific cooperation issues 4、 Developing medical information compilation In order to provide better services, the drug promotion association has a special information department, which is responsible for collecting and sorting out domestic and foreign medical information: Daily editing and sending "medical information briefing"; regular editing and sending "international pharmaceutical industry development trends and R & D information briefing"; regular publishing of Internal Journal "medical research and development information"; strengthening the website construction of the drug promotion association, and constantly reviewing the revised version The website of the Association for the promotion of drugs was adjusted and improved, and the association's dynamic, medical policy and research hot issues were updated in real time 5、 In order to standardize the management and operation, improve the ability of service and development, we will continue to improve the internal management system of personnel and finance In addition, the drug promotion association often sends staff to member units to carry out visits and research activities to understand the needs of member units, so as to make the drug promotion work more targeted and effective Lu Yaohua, executive vice president of China Federation of industrial economy, Rong Jianying, secretary general, and the presidents and secretaries of 17 trade associations managed by the Federation attended the meeting.